RoxithromycinCAS# 80214-83-1 |
- Perindopril Erbumine
Catalog No.:BCC3586
CAS No.:107133-36-8
- Losartan Potassium (DuP 753)
Catalog No.:BCC1080
CAS No.:124750-99-8
- Candesartan
Catalog No.:BCC2558
CAS No.:139481-59-7
- Telmisattan
Catalog No.:BCC3863
CAS No.:144701-48-4
- Imidapril HCl
Catalog No.:BCC3792
CAS No.:89396-94-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 80214-83-1 | SDF | Download SDF |
| PubChem ID | 9567573 | Appearance | Powder |
| Formula | C41H76N2O15 | M.Wt | 837.06727 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 100 mg/mL (119.47 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | (3R,4S,5S,6R,7R,9R,10E,11S,12R,13S,14R)-6-[4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy-10-(2-methoxyethoxymethoxyimino)-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2-one | ||
| SMILES | CCC1C(C(C(C(=NOCOCCOC)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O | ||
| Standard InChIKey | RXZBMPWDPOLZGW-KMAKEOJNSA-N | ||
| Standard InChI | InChI=1S/C41H76N2O15/c1-15-29-41(10,49)34(45)24(4)31(42-53-21-52-17-16-50-13)22(2)19-39(8,48)36(58-38-32(44)28(43(11)12)18-23(3)54-38)25(5)33(26(6)37(47)56-29)57-30-20-40(9,51-14)35(46)27(7)55-30/h22-30,32-36,38,44-46,48-49H,15-21H2,1-14H3/b42-31+/t22-,23?,24+,25+,26-,27?,28?,29-,30?,32?,33+,34-,35?,36-,38?,39-,40?,41-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Roxithromycin is a semi-synthetic macrolide antibiotic.
Target: Antibacterial
Roxithromycin is a semi-synthetic macrolide antibiotic. It is used to treat respiratory tract, urinary and soft tissue infections. Roxithromycin is derived from erythromycin, containing the same 14-membered lactone ring. Roxithromycin prevents bacteria from growing, by interfering with their protein synthesis. Roxithromycin binds to the subunit 50S of the bacterial ribosome, and thus inhibits the translocation of peptides. Roxithromycin has similar antimicrobial spectrum as erythromycin, but is more effective against certain gram-negative bacteria, particularly Legionella pneumophila. From Wikipedia. References: | |||||
Roxithromycin Dilution Calculator
Roxithromycin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.1946 mL | 5.9732 mL | 11.9465 mL | 23.8929 mL | 29.8662 mL |
| 5 mM | 0.2389 mL | 1.1946 mL | 2.3893 mL | 4.7786 mL | 5.9732 mL |
| 10 mM | 0.1195 mL | 0.5973 mL | 1.1946 mL | 2.3893 mL | 2.9866 mL |
| 50 mM | 0.0239 mL | 0.1195 mL | 0.2389 mL | 0.4779 mL | 0.5973 mL |
| 100 mM | 0.0119 mL | 0.0597 mL | 0.1195 mL | 0.2389 mL | 0.2987 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Roxithromycin
- Sorbic acid, 1-p-tolylhydrazide
Catalog No.:BCN2219
CAS No.:802048-02-8
- Helicid
Catalog No.:BCN1056
CAS No.:80154-34-3
- Methyl demethoxycarbonylchanofruticosinate
Catalog No.:BCN1348
CAS No.:80151-89-9
- Tussilagine
Catalog No.:BCN1984
CAS No.:80151-77-5
- L-Alanosine
Catalog No.:BCN7253
CAS No.:5854-93-3
- GSK256066
Catalog No.:BCC2285
CAS No.:801312-28-7
- YC 170
Catalog No.:BCC1212
CAS No.:59946-73-5
- H-D-Phe(3-Cl)-OH
Catalog No.:BCC3167
CAS No.:80126-52-9
- H-Phe(3-Cl)-OH
Catalog No.:BCC3168
CAS No.:80126-51-8
- H-D-Phe(2-Cl)-OH
Catalog No.:BCC3166
CAS No.:80126-50-7
- Boc-D-Phe(3-Cl)-OH
Catalog No.:BCC3169
CAS No.:80102-25-6
- Agatharesinol acetonide
Catalog No.:BCN4574
CAS No.:800389-33-7
- Glochidionionol C
Catalog No.:BCC2641
CAS No.:
- Rosmanol
Catalog No.:BCN8425
CAS No.:80225-53-2
- 2'-O-Galloylquercitrin
Catalog No.:BCN8225
CAS No.:80229-08-9
- Casanthranol
Catalog No.:BCC3746
CAS No.:8024-48-4
- Spiramycin
Catalog No.:BCC4724
CAS No.:8025-81-8
- Nafamostat hydrochloride
Catalog No.:BCC4188
CAS No.:80251-32-7
- PHA-848125
Catalog No.:BCC3839
CAS No.:802539-81-7
- Artemisinic acid
Catalog No.:BCN4336
CAS No.:80286-58-4
- AZD1981
Catalog No.:BCC4506
CAS No.:802904-66-1
- RG7090
Catalog No.:BCC5499
CAS No.:802906-73-6
- Dehydro-δ-tocopherol
Catalog No.:BCN4573
CAS No.:802909-72-4
- Stevenleaf
Catalog No.:BCN5978
CAS No.:80321-63-7
Population-based meta-analysis of roxithromycin pharmacokinetics: dosing implications of saturable absorption and protein binding.[Pubmed:28039274]
J Antimicrob Chemother. 2017 Apr 1;72(4):1129-1136.
Objectives: The macrolide antibiotic Roxithromycin has seen widespread clinical use for several decades; however, no population pharmacokinetic analysis has been published. Early studies indicated saturation of protein binding and absorption at doses within the approved range, which may impact pharmacodynamic target attainment since regimens of 150 mg twice daily and 300 mg once daily are used interchangeably in clinical practice. This study aimed to develop a population-based meta-analysis of Roxithromycin pharmacokinetics, and utilize this model to inform optimal dosing regimens. Methods: Following an extensive search, Roxithromycin pharmacokinetic data were collected or digitized from literature publications. Population pharmacokinetic modelling was undertaken with ADAPT. Dosing simulations were performed to investigate differences in exposure and pharmacodynamic target attainment between dosing regimens. Results: A two-compartment model with saturable absorption described the data ( n = 63); changes in free drug exposure were simulated using a saturable protein binding model. Simulations indicated that a 300 mg daily regimen achieves a 37% and 53% lower total or free AUC ( f AUC), respectively, compared with 150 mg twice daily. These pharmacokinetic differences translated to significantly lower target attainment ( f AUC/MIC ratio >20) with a 300 mg daily regimen at MICs of 0.5 and 1 mg/L (51% and 7%) compared with patients receiving 150 mg twice daily (82% and 54%). Conclusions: Roxithromycin displays saturable absorption and protein binding leading to lower exposure and lower target attainment at MICs >/=0.5 mg/L with widely used once-daily dosing regimens, indicating that twice-daily regimens may be preferable for pathogens less susceptible to Roxithromycin.
Topical delivery of roxithromycin solid-state forms entrapped in vesicles.[Pubmed:28119103]
Eur J Pharm Biopharm. 2017 May;114:96-107.
Recently, considerable interest developed in using newer/improved antibiotics for the treatment of Acne vulgaris. During this study, different Roxithromycin solid-state forms (i.e. crystalline and amorphous) were encapsulated into vesicle systems (niosomes, proniosomes, ufosomes and pro-ufosomes) for dermis targeted delivery. Characterization of the vesicles was done with transmission electron microscopy, light microscopy, droplet size, droplet size distribution, pH, zeta-potential and entrapment efficiency percentage. Finally, comparative release and topical diffusion studies were performed, to evaluate if targeted topical delivery was obtained and if the Roxithromycin solid-state amorphous forms resulted in improved topical delivery. Vesicle systems containing different Roxithromycin (2%) solid-state forms were successfully prepared and characterized. The vesicles showed optimal properties for topical delivery. All carrier systems had topical delivery to the epidermis-dermis, whilst no Roxithromycin was found in the receptor compartment or stratum corneum-epidermis. The niosomes were the leading formulation and the two amorphous forms had better topical delivery than the crystalline form. Successful targeted delivery of Roxithromycin was obtained in the dermis, where the activity against Propionibacterium acnes is needed. The amorphous forms seemed to have held their solid-state form during formulation and in the vesicles, showing improved topical delivery in comparison to the crystalline form.
